FDA Approves Augmentin '875' Supplement Application
The FDA has approved a supplemental application for Augmentin '875' submitted by US Antibiotics.
Published: July 25, 2026
Updated: July 25, 2026
Author: Humanexa Intelligence
Therapeutic area: Infectious Disease / Antibiotic
Asset: FDA
Indication: competitors in infectious disease
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
FDA
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Augmentin '875' enhances US Antibiotics' competitive position in the antibiotic market, which could disrupt existing market dynamics. Pharma strategy teams should evaluate the implications for their portfolios and prepare to respond to competitive pressures.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for any market response from competitors and subsequent sales performance of Augmentin '875'.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.